3 Years Ago
1 Min Read
KRTX shares ran up 61% today. A closer look at what's happening:
Karuna Therapeutics Inc (KRTX) is trading 61% higher at $226.155 today.
- Positive results from its Phase 3 EMERGENT-2 trial for KarXT intended for adults suffering from schizophrenia
- Clinical trial met primary endpoint with a 9.6-point reduction on the Positive and Negative Syndrome Scale (PANSS)
- Clinical trial also met its secondary endpoint, citing reduction of positive symptoms and negative symptoms of schizophrenia
Karuna Therapeutics Inc has been trading between a 52-week high of $161.98 and a 52-week low of $92.26. The stock has a market cap of $6.76 Billion.
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing itsextensive knowledge of neuroscience, the Company is harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives.
Headlines
Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data
InvestorPlace 08-08-22
CinCor, Karuna top healthcare gainers; Reata, uniQure lead losers'' pack
Seeking Alpha 08-08-22
Karuna Therapeutics: Q2 Earnings Insights
Benzinga 08-08-22
Karuna Therapeutics Inc. PT Raised to $278 at Goldman Sachs
Investing.com 08-08-22
Karuna''s stock jumps 42% after sharing promising Phase 3 data for its schizophrenia drug
MarketWatch 08-08-22
Recommended Articles
